PT  - JOURNAL ARTICLE
AU  - Ricardo Coelho
AU  - Ana Sofia Santos
AU  - Raquel Rosa
AU  - Dionísio Maia
AU  - Tiago Sá
AU  - Vânia Caldeira
AU  - Luísa Semedo
AU  - João Cardoso
TI  - The importance of dyspnea and airflow limitation for anxiety and depression in COPD
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P3002
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P3002.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P3002.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - Background: Depression and anxiety are important and frequent comorbidities in COPD, leading to increased morbidity and impaired quality of life.Aim: Evaluate the presence of anxiety and depression in the COPD patients and their relation to the airflow limitation severity, dyspnea and exacerbations.Methods: 100 consecutive COPD patients were stratified according to GOLD (GOLD groups and spirometric stages). Dyspnea was assessed using the Modified Medical Research Council Dyspnea Scale (mMRC). The presence of anxiety and depression was evaluated through the Hospital Anxiety and Depression Scale.Results: The mean age was 65±9 years, 85% were male. The distribution of anxiety/depression according to spirometric stages or GOLD groups (using mMRC) is shown in the tables below:View this table:View this table:The exacerbation history and its relation to anxiety/depression showed that: the 7 patients of group C who had at least 2 exacerbations in the previous year, none had anxiety/depression; from the 27 patients of group D who had at least 2 exacerbations in the previous year, 52% had anxiety and 63% had depression.Conclusion: Anxiety and depression are two significant comorbidities of COPD, being the severity of dyspnea (mMRC≥2) a very important factor for both (groups B,D). Also, the frequency of anxiety and depression was higher with worsening airflow limitation and the exacerbation history had a contribution in the cases where significant dyspnea was present.